


Amendments to the Claims

Please amend the listing of claims as follows:

1. (Original) A compound of structural formula (I):




or a pharmaceutically acceptable salt or a solvate thereof, wherein

R_1 is independently:

hydrogen,
hydroxy,
cyano,
nitro,
halo,
alkyl,
alkoxy,
haloalkyl,
(D)-C(O) R_{15} ,
(D)-C(O)OR₁₅,
(D)-C(O)SR₁₅,
(D)-C(O)-heteroaryl,
(D)-C(O)-heterocyclyl,
(D)-C(O)N(R_{15})₂,
(D)-N(R_{15})₂,
(D)-NR₁₅COR₁₅,
(D)-NR₁₅CON(R_{15})₂,

$(D)-NR_{15}C(O)OR_{15}$,
 $(D)-NR_{15}C(R_{15})=N(R_{15})$,
 $(D)-NR_{15}C(=NR_{15})N(R_{15})_2$,
 $(D)-NR_{15}SO_2R_{15}$,
 $(D)-NR_{15}SO_2N(R_{15})_2$,
 $(D)-NR_{15}(D)\text{-heterocyclyl}$,
 $(D)-NR_{15}(D)\text{-heteroaryl}$,
 $(D)-OR_{15}$,
 OSO_2R_{15} ,
 $(D)-[O]_v(C_3\text{-}C_7\text{ cycloalkyl})$,
 $(D)-[O]_v(D)\text{aryl}$,
 $(D)-[O]_v(D)\text{-heteroaryl}$,
 $(D)-[O]_v(D)\text{-heterocyclyl}$ (wherein heterocyclyl excludes a heterocyclyl
containing a single nitrogen when $v=1$),
 $(D)-SR_{15}$,
 $(D)-SOR_{15}$,
 $(D)-SO_2R_{15}$ or
 $(D)-SO_2N(R_{15})_2$,
wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl are
unsubstituted or substituted;

R_2 is:



R_3 is independently:

$(D)\text{-aryl}$ or
 $(D)\text{-heteroaryl}$,
wherein aryl and heteroaryl are unsubstituted or substituted;

R₄ is H or a bond;

each R₅ is independently:

hydrogen,

halo,

alkyl,

haloalkyl,

hydroxy,

alkoxy,

S-alkyl,

SO₂-alkyl,

O-alkenyl

S-alkenyl

NR₁₅C(O)R₁₅,

NR₁₅SO₂R₁₅,

N(R₁₅)₂,

(D)-cycloalkyl or

(D)-aryl (wherein aryl is phenyl or naphthyl),

(D)-heteroaryl or

(D)-heterocyclyl (wherein heterocyclyl excludes a heterocyclyl containing a single nitrogen), and

wherein aryl, heteroaryl, heterocyclyl, alkyl or cycloalkyl is unsubstituted or substituted, and two adjacent R₅ may form a 4- to 7-membered ring;

each R₆ is independently:

hydrogen,

alkyl,

C(O)-alkyl,

(D)-aryl or

cycloalkyl;

each R₇ is independently:

hydrogen,

alkyl,

(D)-aryl,
 (D)-heteroaryl,
 (D)-N(R₉)₂,
 (D)-NR₉C(O) alkyl,
 (D)-NR₉SO₂ alkyl,
 (D)-SO₂N(R₉)₂,
 (D)-(O)_r alkyl,
 (D)-(O)_r(D)-NR₉COR₉,
 (D)-(O)_r(D)-NR₉SO₂R₉,
 (D)-(O)_r heterocyclyl or
 (D)-(O)_r (alkyl)-heterocyclyl;

each R₈ is independently:

hydrogen,
 alkyl,
 (D)-aryl,
 C(O) alkyl,
 C(O)-aryl,
 SO₂-alkyl or
 SO₂-aryl;

R₉ and R₁₀ are each independently:

hydrogen,
 alkyl or
 cycloalkyl, or

R₉ and R₁₀ together with the nitrogen to which they are attached form a 5- to 8-membered ring optionally containing an additional heteroatom selected from O, S and NR₆,

wherein alkyl and cycloalkyl are unsubstituted or substituted;

R₁₃ is:

hydrogen
 or alkyl;

each R₁₅ is independently;

hydrogen,

alkyl,

haloalkyl,

(D)-cycloalkyl,

(D)-aryl (wherein aryl is phenyl or naphthyl),

(D)-heteroaryl or

(D)-heterocyclyl,

wherein heterocyclyl excludes a heterocyclyl containing a single nitrogen, and

wherein aryl, heteroaryl, heterocyclyl, alkyl and cycloalkyl is unsubstituted or substituted;

Cy is:

aryl,

5- or 6-membered heteroaryl,

5- or 6-membered heterocyclyl or

5- or 7-membered carbocyclyl;

A is a bond, O, S(O)_u, NR₈ or CH₂;

D is a bond or alkylene;

X is N or CH;

Y is O or NR₉;

n is 1 - 4;

o is 0 - 2;

p is 0 - 2;

r is 0 or 1;

s is 0 - 5;

u is 0 - 2;

v is 0 or 1.

2. (Original) The compound of claim 1, wherein

each R_1 is independently:

hydrogen,

hydroxy,

cyano,

nitro,

halo,

alkyl,

alkoxy,

haloalkyl,

(D)- $N(R_{15})_2$,

(D)- $NR_{15}COR_{15}$,

(D)- $NR_{15}CON(R_{15})_2$,

(D)- $NR_{15}C(O)OR_{15}$,

(D)- $NR_{15}C(R_{15})=N(R_{15})$,


(D)- $NR_{15}C(=NR_{15})N(R_{15})_2$,

(D)- $NR_{15}SO_2R_{15}$,

(D)- $NR_{15}SO_2N(R_{15})_2$ or

(D)-heterocyclyl;

R_2 is:



R_3 is (CH_2) -phenyl or (CH_2) -naphthyl, unsubstituted or substituted with one to three substituents selected from the group consisting of cyano, nitro, perfluoroalkoxy, halo, alkyl, (D)-cycloalkyl, alkoxy and haloalkyl;

each R₅ is independently;

hydrogen,
halo,
alkyl,
haloalkyl,
hydroxy,
alkoxy,
S-alkyl,
SO₂-alkyl,
O-alkenyl or
S-alkenyl;

each R₆ is independently:

hydrogen or
alkyl;

each R₇ is independently:

alkyl,
hydrogen,
(D)-aryl,
(D)-heteroaryl,
(D)-N(R₉)₂,
(D)-NR₉C(O)alkyl or
(D)-NR₉SO₂alkyl;

R₉ and R₁₀ are each independently:

hydrogen,
alkyl or
cycloalkyl, or

R₉ and R₁₀ together with the nitrogen to which they are attached form a 5- to 7-membered ring optionally containing an additional heteroatom selected from O, S and NR₆;

each R₁₁ is independently:

alkyl,
OR₁₂,
(D)-aryl,
(D)-cycloalkyl,
(D)-heteroaryl or
halo;

each R₁₂ is independently:

hydrogen,
(D)-aryl or
alkyl;

each R₁₃ is independently:

hydrogen or
C₁ – C₄ alkyl;

R₁₄ is independently selected from the group consisting of;

hydrogen,
halo,
alkyl,
(D)-cycloalkyl,
alkoxy or
phenyl;

R₁₅ is independently:

hydrogen,
halo,
alkyl,
(D)-cycloalkyl,
alkoxy or
phenyl;

Cy is selected from aryl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocyclyl or 5- to 7-membered carbocyclyl;

A is a bond or CH₂;

D is a bond or CH₂;

Y is NR₉ or O;

n is 0, 1 or 2;

o is 0 or 1;

p is 0 or 1;

s is 0 - 3


v is 0 or 1.

3. (Currently Amended) The compound of claim 1 ~~or~~ 2, wherein

each R₁ is independently:

cyano,
 nitro,
 halo,
 alkyl,
 (D)-heterocyclyl,
 (D)-N(R₁₅)₂,
 (D)-NR₁₅COR₁₅,
 (D)-NR₁₅CON(R₁₅)₂,
 (D)-NR₁₅C(O)OR₁₅ or
 (D)-NR₁₅SO₂R₁₅,

R₂ is:



R₃ is (CH₂)-phenyl or (CH₂)-naphthyl, substituted with one or two substituents selected from the group consisting of perfluoroalkoxy, halo, alkyl, alkoxy and haloalkyl;

each R₅ is independently:

hydrogen,
halo,
alkyl,
hydroxy,
S-alkyl,
SO₂-alkyl or
alkoxy;

R₆ is hydrogen;

R₇ is hydrogen;

R₉ and R₁₀ are each independently:

hydrogen or
alkyl, or

R₉ and R₁₀ together with the nitrogen to which they are attached form a 5- to 6-membered ring optionally containing an additional oxygen atom;

R₁₂ is hydrogen or (D)-aryl

each R₁₃ is independently:

hydrogen,
methyl or
ethyl;

R₁₄ is independently:

hydrogen,
halo,
alkyl,
alkoxy or
phenyl;

R₁₅ is independently:

hydrogen,
halo,
alkyl,
alkoxy or
phenyl;

Cy is:

aryl or
heteroaryl;

D is a bond;

n is 1 or 2;

o is 0;


p is 0;

s is 0 - 2.

4. (Currently Amended) The compound of claim 1, ~~2 or 3~~ wherein

R₁ is (D)-heterocyclyl;

R₂ is:



R₃ is (CH₂)-phenyl or (CH₂)-naphthyl, unsubstituted or substituted with one or two halogen atoms;

each R₅ is independently:

hydrogen,
isopropyl,
hydroxy,
alkoxy,

S-alkyl or
SO₂-alkyl;

R₆ is hydrogen;

R₇ is hydrogen;

R₉ and R₁₀ are each independently:

hydrogen or
alkyl, or

R₉ and R₁₀ together with the nitrogen to which they are attached form a 5- to 6-membered ring optionally containing an additional oxygen atom;

Cy is benzene;

s is 0 or 1.

5. (Currently Amended) ~~The compound of any of claims 1 to 4 for use as a~~
A medicament comprising the compound of claim 1.

6. (Currently Amended) ~~Use of the compound of any of claims 1 to 4 for the~~
~~preparation of a medicament for the treatment or prevention of~~ A method of treating or
preventing disorders, diseases or conditions responsive to the inactivation or activation of the
melanocortin-4 receptor in a mammal, the method comprising administering an effective
amount of the compound of claim 1.

7. (Currently Amended) ~~Use according to claim 6 for the preparation of a medicament~~
~~for the treatment or prevention of cancer cachexia.~~ A method of treating or preventing cancer
cachexia, the method comprising administering an effective amount of the compound of
claim 6.

8. (Currently Amended) ~~Use according to claim 6 for the preparation of a medicament~~
~~for the treatment or prevention of muscle wasting.~~ A method of treating or preventing muscle
wasting, the method comprising administering an effective amount of the compound of
claim 6.

9. (Currently Amended) ~~Use according to claim 6 for the preparation of a medicament for the treatment or prevention of anorexia.~~ A method of treating or preventing anorexia, the method comprising administering an effective amount of the compound of claim 6.
10. (Currently Amended) ~~Use according to claim 6 for the preparation of a medicament for the treatment or prevention of anxiety and/or depression.~~ A method of treating or preventing anxiety and/or depression, the method comprising administering an effective amount of the compound of claim 6.
11. (Currently Amended) ~~Use according to claim 6 for the preparation of a medicament for the treatment or prevention of obesity.~~ A method of treating or preventing obesity, the method comprising administering an effective amount of the compound of claim 6.
12. (Currently Amended) ~~Use according to claim 6 for the preparation of a medicament for the treatment or prevention of diabetes mellitus.~~ A method of treating or preventing diabetes mellitus, the method comprising administering an effective amount of the compound of claim 6.
13. (Currently Amended) ~~Use according to claim 6 for the preparation of a medicament for the treatment or prevention of male or female sexual dysfunction.~~ A method of treating or preventing male or female sexual dysfunction, the method comprising administering an effective amount of the compound of claim 6.
14. (Currently Amended) ~~Use according to claim 6 for the preparation of a medicament for the treatment or prevention of erectile dysfunction.~~ A method of treating or preventing erectile dysfunction, the method comprising administering an effective amount of the compound of claim 6.
15. (Currently Amended) A pharmaceutical composition which comprises a compound of ~~any of claims 1 to 4~~claim 1 and a pharmaceutically acceptable carrier.